Aesthetic pharmaceutical company Galderma hosted an event at The Gherkin for the UK launch of its new neuromodulator, Relfydess, on June 3.
The event featured expert insights from Dr Javier Murillo, Miss Priya Chadha, Dr Wojciech Konczalik, Mr Ash Soni and Dr Kuldeep Minocha. Described by speakers as a long-acting botulinum toxin, Relfydess is reported to provide results lasting up to six months, with a rapid onset of action observed in some cases in under 24 hours.
The product is indicated for the treatment of glabellar lines and lateral canthal lines. Relfydess has been in development for over 15 years and was launched in Spain six months ago. It incorporates what the company refers to as ‘pearl technology’, though further details on the mechanism are yet to be disclosed. Significant investment has gone into the research and development of the product, with sustainability also forming part of its strategic positioning.
According to the brand, efforts have been made to minimise waste and improve recyclability across packaging and production processes. More information on clinical data and UK availability is expected in the coming months and Relfydess will be a key topic of discussion at CCR.
Galderma will be Headline Sponsor at CCR on September 25-26.